Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$477.41 USD

477.41
2,104,200

+15.02 (3.25%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $477.56 +0.15 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Zacks Equity Research

Illumina (ILMN) to Develop Synthetic Genomic Data With New Pact

by Zacks Equity Research

Illumina's (ILMN) recent collaboration will allow it to leverage the best-quality synthetic data to remove privacy bottlenecks and accelerate the development of precision medicine.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock for Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) on acquisitions of Cognate BioServices and Vigene Biosciences.

Zacks Equity Research

Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FLQL

Zacks Equity Research

Here's Why You Should Retain Veeva Systems (VEEV) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Veeva Systems (VEEV) owing to its strong product portfolio.

Zacks Equity Research

Study Favors Masimo's (MASI) SedLine for Better Patient Outcome

by Zacks Equity Research

Masimo's (MASI) SedLine is expected to aid in the early identification of patients who are at risk of developing POD.

Zacks Equity Research

Here's Why You Should Retain Ecolab (ECL) Stock Right Now

by Zacks Equity Research

Ecolab (ECL) continues to gain traction from a solid product portfolio and segmental strength. However, segmental weakness remains a woe.

Zacks Equity Research

Veeva Systems' (VEEV) Buyout to Bolster Clinical Offering

by Zacks Equity Research

Veeva Systems' (VEEV) Veracity Logic buyout can help companies to simplify complex processes and speed up clinical trials.

Zacks Equity Research

CVS Health (CVS) Outlines Growth Strategy, Initiates 2022 View

by Zacks Equity Research

CVS Health's (CVS) new strategy capitalizes on the considerable opportunity to make health care more convenient, personalized and affordable for consumers.

Zacks Equity Research

McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Zacks Equity Research

PerkinElmer's (PKI) Latest Kit to Boost COVID-19 Surveillance

by Zacks Equity Research

PerkinElmer's (PKI) newest addition to its SARS-CoV-2 testing portfolio is expected to aid in combating the pandemic by boosting surveillance.

Zacks Equity Research

DENTSPLY SIRONA's (XRAY) New Alliance to Boost Digital Dentistry

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) and 3Shape extend their partnership to simplify digitally oriented workflows for dentists and dental technicians.

Zacks Equity Research

Here's Why You Should Retain Change Healthcare (CHNG) Stock

by Zacks Equity Research

Change Healthcare (CHNG) continues to benefit from robust payment accuracy business. However, intense competition remains a woe.

Zacks Equity Research

Thermo Fisher (TMO) Completes Acquisition of Leading CRO

by Zacks Equity Research

Thermo Fisher's (TMO) acquisition of PPD is likely to bolster its Laboratory Products and Services arm.

Zacks Equity Research

Thermo Fisher (TMO) Gets FDA PMA for Oncomine Dx Target Test

by Zacks Equity Research

Thermo Fisher's (TMO) Oncomine Dx Target Test will allow clinicians to use FFPE tissue samples to spot patients in the United States who may benefit from the important new therapy.

Zacks Equity Research

Here's Why You Should Add Chemed (CHE) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about Chemed (CHE) on strong third-quarter performance and raised Roto-Rooter and earnings guidance for 2021.

Zacks Equity Research

QIAGEN (QGEN), Denovo to Develop CDx Test for Lymphoid Cancer

by Zacks Equity Research

QIAGEN (QGEN) will develop a diagnostic assay that can identify the Denovo Genomic Marker 1 in patients with lymphoid cancer.

Zacks Equity Research

BD's (BDX) Tissuemed Buyout to Boost its Surgical Solutions Arm

by Zacks Equity Research

BD's (BDX) latest acquisition is expected to complement its currently used products and help to support minimally invasive surgeries.

Zacks Equity Research

NEOGEN (NEOG) Inks Deal to Boost Global Genomics Business

by Zacks Equity Research

NEOGEN's (NEOG) latest acquisition of Genetic Veterinary Sciences, Inc. will bolster the global genomics business.

Zacks Equity Research

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from improving adoption of the da Vince Surgical System. Higher production costs are a woe.

Zacks Equity Research

PacBio (PACB)-UCLA Health Tie Up for Rare Diseases' WGS Research

by Zacks Equity Research

PacBio's (PACB) latest research collaboration is expected to identify the causes behind rare diseases and provide more effective treatments.

Zacks Equity Research

OPKO Health (OPK) Receives FDA Nod for the 4Kscore Test

by Zacks Equity Research

OPKO Health (OPK) gets FDA nod for its 4Kscore Test that will further validate its value of being an important tool in the diagnosis of prostate cancer.

Zacks Equity Research

Exact Sciences' (EXAS) Oncotype DX Test Study Data Favorable

by Zacks Equity Research

Exact Sciences' (EXAS) recent study analysis validates that the Oncotype DX test helps identify early-stage, node-positive breast cancer who can avoid chemotherapy in most women.

Zacks Equity Research

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.

Zacks Equity Research

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about QIAGEN (QGEN) on strong third-quarter results and raised 2021 guidance.

Zacks Equity Research

Here's Why You Should Invest in AmerisourceBergen (ABC) Stock

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust pharmaceutical segment.